

Quick Reference Guide for Offering an Additional Dose of COVID-19 Vaccine for Immunocompromised Individuals

Individuals that are moderately to severely immunocompromised will be asked to self-identify and present to a vaccine clinic or their pharmacist or physician. NACI identifies individuals that are moderately to severely immunocompromised as those with the following conditions:

- Active treatment for solid tumour or hematologic malignancies
- Receipt of solid-organ transplant and taking immunosuppressive therapy
- Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, WiskottAldrich syndrome)
- Stage 3 or advanced untreated HIV infection and those with acquired immunodeficiency syndrome
- Active treatment with the following categories of immunosuppressive therapies: anti-B cell therapies (monoclonal antibodies targeting CD19, CD20 and CD22), high-dose systemic corticosteroids (The Canadian Immunization Guide defines high dose steroids treatment as prednisone equivalent of ≥ 2 mg/kg/day or 20 mg/day if weight > 10 kg, for ≥ 14 days), alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive

Based on emerging evidence, NACI now recommends that individuals who are moderately or severely immunocompromised should receive:

- **three doses** of an authorized mRNA vaccine if they have not yet been immunized; or
- **an additional dose** of an authorized mRNA vaccine if they have previously received a one or two dose primary series, including those who received a mixed vaccine schedule.

For individuals who have already received a one dose or two dose primary series, the minimum interval between the last COVID-19 vaccine received and the additional dose is 28 days.

Verification of the condition is not required to offer an additional dose of COVID-19 vaccine.